Insights on cytochrome P450 enzymes and inhibitors obtained through QSAR studies

Molecules

Volumn 17, Issue 8, 2012, Pages 9283-9305

  Sridhar, Jayalakshmi ^a   Liu, Jiawang ^a   Foroozesh, Maryam ^a   Stevens, Cheryl L Klein ^b  

^a XAVIER UNIVERSITY OF LOUISIANA   (United States)

^b WESTERN KENTUCKY UNIVERSITY   (United States)

Author keywords

3D QSAR; Binding active site; CoMFA; Pharmacophore; SAR

Indexed keywords

CYTOCHROME P450; ENZYME INHIBITOR;

CHEMICAL PHENOMENA; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; DRUG ANTAGONISM; ENZYME ACTIVE SITE; HUMAN; HYDROGEN BOND; METABOLISM; PROTEIN BINDING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; THERMODYNAMICS;

CATALYTIC DOMAIN; COMPUTER SIMULATION; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; HYDROGEN BONDING; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MODELS, MOLECULAR; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS;

EID: 84865445577     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules17089283     Document Type: Review

References (84)

1. Nelson, D.R.; Zeldin, D.C.; Hoffman, S.M.; Maltais, L.J.; Wain, H.M.; Nebert, D.W. Comparison of cytochrome p450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 2004, 14, 1-18.
2. Rodriguez-Antona, C.; Ingelman-Sundberg, M. Cytochrome p450 pharmacogenetics and cancer. Oncogene 2006, 25, 1679-1691.
3. Nebert, D.W.; Dalton, T.P. The role of cytochrome p450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat. Rev. Cancer 2006, 6, 947-960.
4. Gibson, P.; Gill, J.H.; Khan, P.A.; Seargent, J.M.; Martin, S.W.; Batman, P.A.; Griffith, J.; Bradley, C.; Double, J.A.; Bibby, M.C.; et al. Cytochrome p450 1b1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: Implications for drug development. Mol. Cancer Ther. 2003, 2, 527-534.
5. Murray, G.I.; Taylor, M.C.; McFadyen, M.C.; McKay, J.A.; Greenlee, W.F.; Burke, M.D.; Melvin, W.T. Tumor-specific expression of cytochrome p450 CYP1B1. Cancer Res. 1997, 57, 3026-3031.
6. Tokizane, T.; Shiina, H.; Igawa, M.; Enokida, H.; Urakami, S.; Kawakami, T.; Ogishima, T.; Okino, S.T.; Li, L.C.; Tanaka, Y.; et al. Cytochrome p450 1b1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin. Cancer Res. 2005, 11, 5793-5801.
7. Su, J.M.; Lin, P.; Wang, C.K.; Chang, H. Overexpression of cytochrome p450 1b1 in advanced non-small cell lung cancer: A potential therapeutic target. Anticancer Res. 2009, 29, 509-515.
8. Aung, P.P.; Oue, N.; Mitani, Y.; Nakayama, H.; Yoshida, K.; Noguchi, T.; Bosserhoff, A.K.; Yasui, W. Systematic search for gastric cancer-specific genes based on sage data: Melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer. Oncogene 2006, 25, 2546-2557.
9. Karlgren, M.; Gomez, A.; Stark, K.; Svard, J.; Rodriguez-Antona, C.; Oliw, E.; Bernal, M.L.; Ramon y Cajal, S.; Johansson, I.; Ingelman-Sundberg, M. Tumor-specific expression of the novel cytochrome p450 enzyme, CYP2W1. Biochem. Biophys. Res. Commun. 2006, 341, 451-458.
10. Bruno, R.D.; Njar, V.C. Targeting cytochrome p450 enzymes: A new approach in anti-cancer drug development. Bioorg. Med. Chem. 2007, 15, 5047-5060.
11. Mace, K.; Bowman, E.D.; Vautravers, P.; Shields, P.G.; Harris, C.C.; Pfeifer, A.M. Characterisation of xenobiotic-metabolising enzyme expression in human bronchial mucosa and peripheral lung tissues. Eur. J. Cancer 1998, 34, 914-920.
12. Hashizume, T.; Imaoka, S.; Mise, M.; Terauchi, Y.; Fujii, T.; Miyazaki, H.; Kamataki, T.; Funae, Y. Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J. Pharmacol. Exp. Ther. 2002, 300, 298-304.
13. Murray, G.I. The role of cytochrome p450 in tumour development and progression and its potential in therapy. J. Pathol. 2000, 192, 419-426.
14. Gonzalez, F.J. The use of gene knockout mice to unravel the mechanisms of toxicity and chemical carcinogenesis. Toxicol. Lett. 2001, 120, 199-208.
15. Lohr, M.; McFadyen, M.C.; Murray, G.I.; Melvin, W.T. Cytochrome p450 enzymes and tumor therapy. Mol. Cancer Ther. 2004, 3, 1503; author reply 1503-1504.
16. McFadyen, M.C.; Melvin, W.T.; Murray, G.I. Cytochrome p450 enzymes: Novel options for cancer therapeutics. Mol. Cancer Ther. 2004, 3, 363-371.
17. Roy, K.; Roy, P.P. Qsar of cytochrome inhibitors. Expert Opin. Drug Metab. Toxicol. 2009, 5, 1245-1266.
18. Lewis, D.F.; Lake, B.G.; Dickins, M. Quantitative structure-activity relationships (qsars) in inhibitors of various cytochromes p450: The importance of compound lipophilicity. J. Enzyme Inhib. Med. Chem. 2007, 22, 1-6.
19. Lewis, D.F.; Modi, S.; Dickins, M. Structure-activity relationship for human cytochrome p450 substrates and inhibitors. Drug Metab. Rev. 2002, 34, 69-82.
20. Ekins, S.; de Groot, M.J.; Jones, J.P. Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites. Drug Metab. Dispos. 2001, 29, 936-944.
21. Li, H.; Sun, J.; Fan, X.; Sui, X.; Zhang, L.; Wang, Y.; He, Z. Considerations and recent advances in qsar models for cytochrome p450-mediated drug metabolism prediction. J. Comput. Aided Mol. Des. 2008, 22, 843-855.
22. Lewis, D.F. Quantitative structure-activity relationships (qsars) within the cytochrome p450 system: Qsars describing substrate binding, inhibition and induction of p450s. Inflammopharmacology 2003, 11, 43-73.
23. Gleeson, M.P.; Davis, A.M.; Chohan, K.K.; Paine, S.W.; Boyer, S.; Gavaghan, C.L.; Arnby, C.H.; Kankkonen, C.; Albertson, N. Generation of in-silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition qsar models. J. Comput. Aided Mol. Des. 2007, 21, 559-573.
24. Miller, G.P. Advances in the interpretation and prediction of CYP2E1 metabolism from a biochemical perspective. Expert Opin. Drug Metab. Toxicol. 2008, 4, 1053-1064.
25. Free, S.M.J.; Wilson, J.W.A. A mathematical contribution to structure activity studies. J. Med. Chem. 1964, 7, 395-399.
26. Hansch, C.; Fujita, T. P-σ-π analysis. A method for the correlation of biological activity and chemical structure. J. Am. Chem. Soc. 1964, 86, 1616-1626.
27. Hansch, C. A quantitative approach to biochemical structure-activity relationships. Acc. Chem. Res. 1969, 2, 232-239.
28. Cramer, R.D.; Patterson, D.E.; Bunce, J.D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
29. Chen, L.; Gasteiger, J. Knowledge discovery in reaction databases: Landscaping organic reactions by a self organizing neural network. J. Am. Chem. Soc. 1997, 119, 4033-4042.
30. Espinosa, G.; Arenas, A.; Giralt, F. An integrated som-fuzzy artmap neural system for the evaluation of toxicity. J. Chem. Inf. Comput. Sci. 2002, 42, 343-359.
31. Yaffe, D.; Cohen, Y.; Espinosa, G.; Arenas, A.; Giralt, F. Fuzzy artmap and back-propagation neural networks based quantitative structure-property relationships (QSPRs) for octanol-water partition coefficient of organic compounds. J. Chem. Inf. Comput. Sci. 2002, 42, 162-183.
32. Butina, D.; Gola, J.M. Modeling aqueous solubility. J. Chem. Inf. Comput. Sci. 2003, 43, 837-841.
33. Schuurmann, G.; Aptula, A.O.; Kuhne, R.; Ebert, R.U. Stepwise discrimination between four modes of toxic action of phenols in the tetrahymena pyriformis assay. Chem. Res. Toxicol. 2003, 16, 974-987.
34. Yamashita, F.; Hashida, M. In silico approaches for predicting adme properties of drugs. Drug Metab. Pharmacokinet. 2004, 19, 327-338.
35. Lewis, D.F.; Dickins, M. Substrate sars in human P450S. Drug Discov. Today 2002, 7, 918-925.
36. Lewis, D.F.; Jacobs, M.N.; Dickins, M.; Lake, B.G. Quantitative structure-activity relationships for inducers of cytochromes P450 and nuclear receptor ligands involved in P450 regulation within the CYP1, CYP2, CYP3 and CYP4 families. Toxicology 2002, 176, 51-57.
37. Gonzalez, J.; Marchand-Geneste, N.; Giraudel, J.L.; Shimada, T. Docking and qsar comparative studies of polycyclic aromatic hydrocarbons and other procarcinogen interactions with cytochromes P450 1A1 and 1B1. SAR QSAR Environ. Res. 2012, 23, 87-109.
38. Shimada, T.; Oda, Y.; Gillam, E.M.; Guengerich, F.P.; Inoue, K. Metabolic activation of polycyclic aromatic hydrocarbons and other procarcinogens by cytochromes P450 1A1 and P450 1B1 allelic variants and other human cytochromes P450 in salmonella typhimurium NM2009. Drug Metab. Dispos. 2001, 29, 1176-1182.
39. Breinholt, V.M.; Offord, E.A.; Brouwer, C.; Nielsen, S.E.; Brosen, K.; Friedberg, T. In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. Food Chem. Toxicol. 2002, 40, 609-616.
40. Iori, F.; da Fonseca, R.; Ramos, M.J.; Menziani, M.C. Theoretical quantitative structure-activity relationships of flavone ligands interacting with cytochrome P450 1A1 and 1A2 isozymes. Bioorg. Med. Chem. 2005, 13, 4366-4374.
41. Sridhar, J.; Ellis, J.; Dupart, P.; Liu, J.; Stevens, C.L.K.; Foroozesh, M. Development of flavone propargyl ethers as potent and selective inhibitors of cytochrome P450 enzymes 1A1 and 1A2. Communicated 2012, in press.
42. Aiello, S.; Wells, G.; Stone, E.L.; Kadri, H.; Bazzi, R.; Bell, D.R.; Stevens, M.F.; Matthews, C.S.; Bradshaw, T.D.; Westwell, A.D. Synthesis and biological properties of benzothiazole, benzoxazole, and chromen-4-one analogues of the potent antitumor agent 2-(3,4- dimethoxyphenyl)-5-fluorobenzothiazole (PMX 610, NSC 721648). J. Med. Chem. 2008, 51, 5135-5139.
43. Pan, J.; Liu, G.Y.; Cheng, J.; Chen, X.J.; Ju, X.L. CoMFA and molecular docking studies of benzoxazoles and benzothiazoles as CYP450 1A1 inhibitors. Eur. J. Med. Chem. 2010, 45, 967-972.
44. Lewis, D.F.; Broughton, H.B. Molecular binding interactions: Their estimation and rationalization in qsars in terms of theoretically derived parameters. ScientificWorldJournal 2002, 2, 1776-1802.
45. Lewis, D.F. Molecular modeling of human cytochrome P450-substrate interactions. Drug Metab. Rev. 2002, 34, 55-67.
46. Lewis, D.F. Modelling human cytochrome P450-substrate interactions. Ernst Schering Res. Found Workshop 2002, 37, 235-248.
47. Sridhar, J.; Jin, P.; Liu, J.; Foroozesh, M.; Stevens, C.L. In silico studies of polyaromatic hydrocarbon inhibitors of cytochrome P450 enzymes 1A1, 1A2, 2A6, and 2B1. Chem. Res. Toxicol. 2010, 23, 600-607.
48. Roy, K.; Roy, P.P. Comparative qsar studies of CYP1A2 inhibitor flavonoids using 2D and 3D descriptors. Chem. Biol. Drug Des. 2008, 72, 370-382.
49. Sridhar, J.; Foroozesh, M.; Stevens, C.L. QSAR models of cytochrome P450 enzyme 1A2 inhibitors using comfa, comsia and hqsar. SAR QSAR Environ. Res. 2011, 22, 681-697.
50. Korhonen, L.E.; Rahnasto, M.; Mahonen, N.J.; Wittekindt, C.; Poso, A.; Juvonen, R.O.; Raunio, H. Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J. Med. Chem. 2005, 48, 3808-3815.
51. Novotarskyi, S.; Sushko, I.; Korner, R.; Pandey, A.K.; Tetko, I.V. A comparison of different qsar approaches to modeling CYP450 1A2 inhibition. J. Chem. Inf. Model. 2011, 51, 1271-1280.
52. Vasanthanathan, P.; Taboureau, O.; Oostenbrink, C.; Vermeulen, N.P.; Olsen, L.; Jorgensen, F.S. Classification of cytochrome P450 1A2 inhibitors and noninhibitors by machine learning techniques. Drug Metab. Dispos. 2009, 37, 658-664.
53. Rahnasto, M.; Wittekindt, C.; Juvonen, R.O.; Turpeinen, M.; Petsalo, A.; Pelkonen, O.; Poso, A.; Stahl, G.; Holtje, H.D.; Raunio, H. Identification of inhibitors of the nicotine metabolising CYP2A6 enzyme - An in silico approach. Pharmacogenomics J. 2008, 8, 328-338.
54. Rahnasto, M.; Raunio, H.; Poso, A.; Wittekindt, C.; Juvonen, R.O. Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme. J. Med. Chem. 2005, 48, 440-449.
55. Roy, K.; Roy, P.P. Exploring qsar and qaar for inhibitors of cytochrome P450 2A6 and 2A5 enzymes using gfa and g/pls techniques. Eur. J. Med. Chem. 2009, 44, 1941-1951.
56. Rahnasto, M.K.; Raunio, H.A.; Wittekindt, C.; Salminen, K.A.; Leppanen, J.; Juvonen, R.O.; Poso, A.; Lahtela-Kakkonen, M.K. Identification of novel CYP2A6 inhibitors by virtual screening. Bioorg. Med. Chem. 2011, 19, 7186-7193.
57. Gharaghani, S.; Khayamian, T.; Keshavarz, F. Docking, molecular dynamics simulation studies, and structure-based QSAR model on cytochrome P450 2A6 inhibitors. Struct. Chem. 2012, 23, 341-350.
58. Denton, T.T.; Zhang, X.; Cashman, J.R. 5-Substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6. J. Med. Chem. 2005, 48, 224-239.
59. Van Damme, S.; Bultinck, P. Conceptual dft properties-based 3D QSAR: Analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme. J. Comput. Chem. 2009, 30, 1749-1757.
60. DeVore, N.M.; Smith, B.D.; Wang, J.L.; Lushington, G.H.; Scott, E.E. Key residues controlling binding of diverse ligands to human cytochrome P450 2A enzymes. Drug Metab. Dispos. 2009, 37, 1319-1327.
61. Lesigiarska, I.; Pajeva, I.; Yanev, S. Quantitative structure-activity relationship (QSAR) and three-dimensional QSAR analysis of a series of xanthates as inhibitors and inactivators of cytochrome P450 2B1. Xenobiotica 2002, 32, 1063-1077.
62. Lewis, D.F.; Ito, Y.; Lake, B.G. Quantitative structure-activity relationships (QSARs) for inhibitors and substrates of CYP2B enzymes: Importance of compound lipophilicity in explanation of potency differences. J. Enzyme Inhib. Med. Chem. 2010, 25, 679-684.
63. Korhonen, L.E.; Turpeinen, M.; Rahnasto, M.; Wittekindt, C.; Poso, A.; Pelkonen, O.; Raunio, H.; Juvonen, R.O. New potent and selective cytochrome P450 2B6 (CYP2B6) inhibitors based on three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis. Br. J. Pharmacol. 2007, 150, 932-942.
64. Roy, P.P.; Roy, K. Pharmacophoremapping,molecular docking and QSAR studies of structurally diverse compounds as CYP2B6 inhibitors. Mol. Simul. 2010, 36, 887-905.
65. Jones, J.P.; He, M.; Trager, W.F.; Rettie, A.E. Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. Drug Metab. Dispos. 1996, 24, 1-6.
66. Rao, S.; Aoyama, R.; Schrag, M.; Trager, W.F.; Rettie, A.; Jones, J.P. A refined 3-dimensional qsar of cytochrome P450 2C9: Computational predictions of drug interactions. J. Med. Chem. 2000, 43, 2789-2796.
67. Ekins, S.; Bravi, G.; Binkley, S.; Gillespie, J.S.; Ring, B.J.; Wikel, J.H.; Wrighton, S.A. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors. Drug Metab. Dispos. 2000, 28, 994-1002.
68. Mancy, A.; Broto, P.; Dijols, S.; Dansette, P.M.; Mansuy, D. The substrate binding site of human liver cytochrome P450 2C9: An approach using designed tienilic acid derivatives and molecular modeling. Biochemistry 1995, 34, 10365-10375.
69. Lewis, D.F.; Lake, B.G.; Ito, Y.; Dickins, M. Lipophilicity relationships in inhibitors of CYP2C9 and CYP2C19 enzymes. J. Enzyme Inhib. Med. Chem. 2006, 21, 385-389.
70. Jonsdottir, S.O.; Ringsted, T.; Nikolov, N.G.; Dybdahl, M.; Wedebye, E.B.; Niemela, J.R. Identification of cytochrome P450 2D6 and 2C9 substrates and inhibitors by qsar analysis. Bioorg. Med. Chem. 2012, 20, 2042-2053.
71. DailyMed. Available on: http://dailymed.Nlm.Nih.Gov/dailymed. (accessed on 3 August 2012)
72. Suzuki, H.; Kneller, M.B.; Haining, R.L.; Trager, W.F.; Rettie, A.E. (+)-n-3-Benzyl-nirvanol and (-)-n-3-benzyl-phenobarbital: New potent and selective in vitro inhibitors of CYP2C19. Drug Metab. Dispos. 2002, 30, 235-239.
73. Suzuki, H.; Kneller, M.B.; Rock, D.A.; Jones, J.P.; Trager, W.F.; Rettie, A.E. Active-site characteristics of CYP2C19 and CYP2C9 probed with hydantoin and barbiturate inhibitors. Arch. Biochem. Biophys. 2004, 429, 1-15.
74. Locuson, C.W., 2nd; Rock, D.A.; Jones, J.P. Quantitative binding models for CYP2C9 based on benzbromarone analogues. Biochemistry 2004, 43, 6948-6958.
75. Locuson, C.W.; Wahlstrom, J.L. Three-dimensional quantitative structure-activity relationship analysis of cytochromes P450: Effect of incorporating higher-affinity ligands and potential new applications. Drug Metab. Dispos. 2005, 33, 873-878.
76. Cohen, G.M.; Mannering, G.J. Involvement of a hydrophobic site in the inhibition of the microsomal p-hydroxylation of aniline by alcohols. Mol. Pharmacol. 1973, 9, 383-397.
77. Wang, M.H.; Wade, D.; Chen, L.; White, S.; Yang, C.S. Probing the active sites of rat and human cytochrome P450 2E1 with alcohols and carboxylic acids. Arch. Biochem. Biophys. 1995, 317, 299-304.
78. Vaz, R.J.; Nayeem, A.; Santone, K.; Chandrasena, G.; Gavai, A.V. A 3D-QSAR model for CYP2D6 inhibition in the aryloxypropanolamine series. Bioorg. Med. Chem. Lett. 2005, 15, 3816-3820.
79. Ai, C.; Li, Y.; Wang, Y.; Chen, Y.; Yang, L. Insight into the effects of chiral isomers quinidine and quinine on CYP2D6 inhibition. Bioorg. Med. Chem. Lett. 2009, 19, 803-806.
80. Hammann, F.; Gutmann, H.; Baumann, U.; Helma, C.; Drewe, J. Classification of cytochrome P(450) activities using machine learning methods. Mol. Pharm. 2009, 6, 1920-1926.
81. Didziapetris, R.; Dapkunas, J.; Sazonovas, A.; Japertas, P. Trainable structure-activity relationship model for virtual screening of CYP3A4 inhibition. J. Comput. Aided Mol. Des. 2010, 24, 891-906.
82. Roy, P.P.; Roy, K. Qsar studies of cyp2d6 inhibitor aryloxypropanolamines using 2D and 3D descriptors. Chem. Biol. Drug Des. 2009, 73, 442-455.
83. Roy, K.; Pratim Roy, P. Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques. Eur. J. Med. Chem. 2009, 44, 2913-2922.
84. Mao, B.; Gozalbes, R.; Barbosa, F.; Migeon, J.; Merrick, S.; Kamm, K.; Wong, E.; Costales, C.; Shi, W.; Wu, C.; et al. QSAR modeling of in vitro inhibition of cytochrome P450 3A4. J. Chem. Inf. Model. 2006, 46, 2125-2134.